104 terminated. 104 Phase 3, 17 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 104 | Terminated 104 |
| Phase 2 | 17 | Terminated 17 |
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL Hypericin, Placebo - CTCL/ Mycosis Fungoides, CTCL | Phase 3 | Terminated | Soligenix | 70 | 2025-01-07 | 2026-07-13 |
| [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma [68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose - Marginal Zone Lymphoma | Phase 3 | Terminated | Pentixapharm AG | 8 | 2024-05-20 | 2026-04-28 |
| NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg - Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 / Phase 3 | Terminated | Nektar Therapeutics | 15 | 2023-02-23 | 2026-10-16 |
| A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) T-Guard, Ruxolitinib - Steroid-Refractory Acute Graft Versus Host Disease | Phase 3 | Terminated | Xenikos | 12 | 2022-06-16 | 2024-08-27 |
| A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation AB-205, Placebo - Hodgkin Lymphoma, Non Hodgkin Lymphoma | Phase 3 | Terminated | Angiocrine Bioscience | 130 | 2022-02-21 | 2025-02-04 |
| Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) Zandelisib, Rituximab, Bendamustine - Follicular Lymphoma (FL), Non Hodgkin Lymphoma | Phase 3 | Terminated | MEI Pharma, Inc. | 82 | 2021-08-13 | 2024-11-04 |
| SPARK-ALL: Calaspargase Pegol in Adults With ALL Calaspargase pegol (S95015) - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Terminated | Institut de Recherches Internationales Servier | 42 | 2021-07-07 | 2026-10-29 |
| Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) Efprezimod alfa, Placebo, Methotrexate - Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease | Phase 3 | Terminated | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 11 | 2021-01-05 | 2023-02-08 |
| A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). Polatuzumab Vedotin, Bendamustine, Rituximab - Diffuse, Large B-Cell, Lymphoma | Phase 3 | Terminated | Hoffmann-La Roche | 42 | 2020-07-10 | 2023-03-03 |
| A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH Emapalumab-Lzsg - Hemophagocytic Lymphohistiocytoses | Phase 2 / Phase 3 | Terminated | Swedish Orphan Biovitrum | 7 | 2020-06-02 | 2023-10-06 |
| Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1 VTS-270 - Niemann-Pick Disease, Type C | Phase 2 / Phase 3 | Terminated | Mandos LLC | 2 | 2019-12-02 | 2023-12-26 |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) Ublituximab, Umbralisib, Venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 / Phase 3 | Terminated | TG Therapeutics, Inc. | 277 | 2019-05-16 | 2024-04-19 |
| A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) JHL1101, MabThera - Diffuse Large B-Cell Lymphoma | Phase 3 | Terminated | JHL Biotech, Inc. | 8 | 2018-11-13 | 2020-01-09 |
| Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System Adrabetadex - Niemann-Pick Type C Disease | Phase 3 | Terminated | Mandos LLC | 27 | 2018-06-18 | 2024-01-17 |
| Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 3 | Terminated | Kiadis Pharma | 63 | 2017-11-29 | 2022-05-24 |
| A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, Nivolumab, Brentuximab vedotin - Hodgkin's Disease | Phase 3 | Terminated | Bristol-Myers Squibb | 23 | 2017-06-26 | 2024-01-10 |
| Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Naloxone Hydrochloride Lotion, 0.5%, Placebo Lotion - Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous | Phase 3 | Terminated | Elorac, Inc. | 59 | 2017-01-01 | 2022-10-28 |
| Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) Avelumab, Utomilumab, Rituximab - Diffuse Large B-Cell Lymphoma | Phase 3 | Terminated | Pfizer | 29 | 2016-12-16 | 2020-12-17 |
| Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI CDZ173 - Activated PI3Kdelta Syndrome (APDS); PASLI Disease | Phase 2 / Phase 3 | Terminated | Pharming Technologies B.V. | 37 | 2016-09-08 | 2026-03-30 |
| A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma Ibrutinib, Rituximab, Ifosfamide - Lymphoma, Non-Hodgkin | Phase 3 | Terminated | Janssen Research & Development, LLC | 72 | 2016-07-01 | 2022-12-02 |
Showing 20 of 104. Sign in to see all of them.
Lymphoma (25) · Lymphoma, Follicular (23) · Lymphoma, Non-Hodgkin (22) · Lymphoma, Large B-Cell, Diffuse (18) · Leukemia, Lymphocytic, Chronic, B-Cell (17) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (17) · Leukemia (13) · Lymphoma, B-Cell, Marginal Zone (9) · Hodgkin Disease (7) · Mycosis Fungoides (7) · Myelodysplastic Syndromes (7) · Lymphoma, Mantle-Cell (6) · Lymphoma, T-Cell, Cutaneous (6) · Neoplasms (6) · Sezary Syndrome (6)
Hemic and Lymphatic Diseases (104) · Immune System Diseases (95) · Immunoproliferative Disorders (93) · Lymphoproliferative Disorders (93) · Neoplasms by Histologic Type (91) · Neoplasms (88) · Lymphoma (44) · Hematologic Diseases (38) · Lymphoma, Non-Hodgkin (37) · Leukemia, Lymphoid (35) · Pathological Conditions, Signs and Symptoms (29) · Pathologic Processes (27) · Leukemia (26) · Disease Attributes (25)
Rituximab (34) · Cyclophosphamide (18) · Vincristine (13) · Doxorubicin (11) · Prednisone (10) · Etoposide (9) · Bendamustine Hydrochloride (7) · Methotrexate (7) · Radiotherapy (7) · idelalisib (7) · Bleomycin (5) · Dexamethasone (5) · Filgrastim (5) · ibritumomab tiuxetan (5) · ofatumumab (5)
Gilead Sciences (7) · Spectrum Pharmaceuticals, Inc (6) · European Organisation for Research and Treatment of Cancer - EORTC (5) · M.D. Anderson Cancer Center (4) · Novartis Pharmaceuticals (4) · Pfizer (4) · Biogen (3) · Hoffmann-La Roche (3) · Lymphoma Study Association (3) · Mandos LLC (3) · TG Therapeutics, Inc. (3) · French Innovative Leukemia Organisation (2) · Kiadis Pharma (2) · Masonic Cancer Center, University of Minnesota (2) · SWOG Cancer Research Network (2)
United States (75) · France (38) · United Kingdom (33) · Italy (32) · Spain (32) · Belgium (30) · Canada (29) · Poland (26) · Germany (25) · Australia (21) · Czechia (18) · Russia (16) · South Korea (16) · Netherlands (15) · Hungary (14)
Alessandro M Gianni, MD (1) · Alfred Reiter, MD (1) · Amrita Y. Krishnan MD, MD (1) · Andrea Velardi, MD (1) · Andreas Buck, Prof. Dr. (1) · Angela Smith, MD (1) · Anton Hagenbeek, MD, PhD (1)
PMID 26373676, PMID 30770362, PMID 42699559, PMID 15226337, PMID 15247354, PMID 19270260, PMID 19414675, PMID 20850381, PMID 21073974, PMID 21196441, PMID 22658895, PMID 22924950, PMID 23834234, PMID 24895339, PMID 25103870, PMID 25882396, PMID 27083332, PMID 27282998, PMID 28251914, PMID 28257752, PMID 28983060, PMID 29061568, PMID 29782642, PMID 30341058, PMID 30546948, PMID 30617197, PMID 30916608, PMID 30995176, PMID 31053601, PMID 32289160, PMID 32505213, PMID 32599655, PMID 32632956, PMID 32810220, PMID 32816215, PMID 33026184, PMID 33054054, PMID 33054084, PMID 33097974, PMID 33211799, PMID 33542479, PMID 33651099, PMID 33683917, PMID 33973233, PMID 34161631, PMID 34323957, PMID 34323958, PMID 34389273, PMID 34572728, PMID 34687398
2015 (4), 2016 (4), 2009 (2), U10CA032102 (2), 2004 (1), 2008 (1), 2014 (1), 2017 (1), P30CA036727 (1), P30CA069533 (1), U01HL069294 (1), U10CA031946 (1), U10CA081920 (1), U10CA101165 (1), U10HL069294 (1)